| Project/Area Number |
21590497
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
TSUJI Takao 藤田保健衛生大学, 医学部, 教授 (60171998)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 結核抗原 / 毒素原性大腸菌 / 下痢毒素(LT) / Ag85A, B, C / CFP-10 / BCG / Ag85A,B,C / EAST-6 / PPE |
|---|
| Research Abstract |
Ag85A, B or C of BCG and CFP-10, EAST-6, PPE or TB7.3 of Tbc were overproduced and purified. Although TB7.3 was aggregated and could not be purified, the others were purified and used for antigens to immunize mice with mutant LT as the mucosal adjuvant. We determined that the mice immunized with Ag85A, B or C plus mLT were not effective for prevention of BCG or Tbc infection. As we need much time to determine whether CFP-10, EAST-6, PP E or TB7.3 from Tbc will be effective to Tbc infection as the vaccine, we are doing some experiments to determine it.
|
